HSPA8P20

Across TCGA pan-cancer cohorts, HSPA8P20 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated HSPA8P20 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HSPA8P20 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated HSPA8P20 expression acts as an unfavorable survival marker, although some lineages such as UCS and LAML show a favorable association.

LIHC, UCS, and MESO are the cancer types where HSPA8P20 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.353	0.709	.006	51	view →
UCS	DFS	Tertile	All	0.748	0.365	.017	48	view →
MESO	OS	Tertile	IV	0.036	0.602	<.001	45	view →
KICH	DFS	Tertile	II,III,IV	0.043	0.950	<.001	45	view →
LAML	DFS	Quartile	All	0.687	0.259	.002	18	view →
READ	OS	Tertile	IV	0.615	0.933	.027	18	view →
COAD	DFS	Tertile	IV	0.167	0.530	.016	18	view →
THYM	OS	Median	All	1.000	0.736	.001	13	view →
KIRC	DFS	Tertile	All	0.437	0.669	.014	12	view →
ACC	DFS	Tertile	All	0.337	0.681	.035	12	view →
LGG	DFS	Tertile	All	0.746	0.844	.032	6	view →
HNSC	OS	Tertile	IV	0.810	0.686	.034	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

HSPA8P20–LIHC (OS)

Open the LIHC breakdown →